REM1 and COVID-19: Notwithstanding, Rem was a potent Nrf2 activator and inhibitor of the SARS-CoV2 induced formation of cellular PSSG, but these effects of Rem occurred later in the infection process (from 24 hpi onward) compared with Nel (6 hpi), which may explain the limited cytoprotection activity of this antiviral in our in vitro model of SAR-CoV2 infection, as well as the disappointing results obtained in COVID-19 therapy [49].